Loading company…
Wuhan Xinsheng Technology develops nanorobots for thrombolysis and tumor treatment.
Founded in 2024 and based in Wuhan, China, Wuhan Xinsheng Technology develops biomedical nanorobots for precision medicine. Its work includes a thrombolysis nanorobot intended to address challenges in traditional thrombosis treatment, as well as nanorobots for tumor treatment. In March 2026, it received venture funding from Yangtze River Industry Fund and Chen Qingliu.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in